RVMD·Revolution Medicines, Inc.
RVMD|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $-2.43 | - | - |
| Q2'26 | $-2.02 | $-2.34 | -16.0% |
| Q4'24 | $-0.96 | $-1.12 | -16.1% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $19M | - | - |
| Q2'26 | $17M | $0 | -100.0% |
| Q4'24 | - | $0 | - |
RVMD|Monthly Returns
Market Data
RVMD Stock Snapshot
- Market cap
- 40.93B
- Day range
- $188.18 – $197.12
- News sentiment
- 64/100 · Bullish
- Analyst target
- $251.21 (+31.9%)
- Consensus
- Buy · 30 analysts
The setup on Revolution Medicines, Inc. is patient: consolidation, not accumulation or distribution. The stock is liquid enough that positioning changes get absorbed without distorting the trend.
Behaviour On Record
What RVMD's own history says about today's numbers
- Realized volatility (21d)
- 34.5% 9th pct
- Below its peak
- -13.9%
- vs 200-day average
- +36.8%
- Up days (1y)
- 57%
Revolution Medicines, Inc. is currently running 34.5% annualised volatility over the last 21 sessions. Measured against RVMD's own 6 years of daily returns rather than a market-wide average, that is the 9th percentile — unusually subdued by its own history, against a typical reading of 55.7%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
RVMD is trading -13.9% below its running peak. Across 6 full years on file, its median worst-drawdown-in-a-year was -44.2%, and the deepest was -55.9% in 2021. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.
Price sits +36.8% from its 200-day moving average. Against every other day in its history, that gap ranks at the 80th percentile — a wider gap than this stock usually carries. Over the past year RVMD closed higher on 57% of sessions, and it is currently 1 session into a falling streak.
On September specifically: over 7 years of records, RVMD finished the month higher 3 of 7 times, with a median return of -6.7% and an average of +1.3%. Its strongest month historically has been November at +16.1% on average, its weakest May at -2.2%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: RVMD has opened more than 2% away from the prior close in 268 of 1,657 sessions (16.2% of the time), with the largest gaps running +24.8% and -20.5%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
All figures computed from 1,658 daily closes between 2020-02-13 and 2026-09-18, split-adjusted, recomputed daily. Percentiles are against RVMD's own 7-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of RVMD's sector?
Revolution Medicines, Inc. sits in the Health Care sector, currently ranked 4th of 11 GICS sectors by relative-strength rotation score (improving).
- Sector rank
- #4 of 11
- Sector state
- Improving
- Sector rotation score
- 100
Analyst Rating Changes
Are analysts turning bullish or bearish on RVMD?
Morgan Stanley most recently initiated coverage on Revolution Medicines, Inc. to Overweight on Sep 10, 2026 with a price target of $255. Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.
- Latest action
- Morgan Stanley — Overweight
- 90-day upgrades
- 0
- 90-day downgrades
- 0
- Net rating momentum
- 0
RVMD Competitive Positioning
- RVMDyou're hereRevolution Medicines, Inc.$40.9B-0.23%
- VRTXVertex Pharmaceuticals Incorporated$128.8B+0.76%
- MRNAModerna, Inc.$61.5B-0.10%
- CRSPCRISPR Therapeutics AG$5.5B+1.17%
- RXRXRecursion Pharmaceuticals Inc.$2.1B-0.78%
- DNAGinkgo Bioworks Holdings Inc.$530.6M-0.13%
